US 12,233,109 B2
Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
Seulki Lee, Baltimore, MD (US); Ted M. Dawson, Baltimore, MD (US); Han Seok Ko, Baltimore, MD (US); Valina L. Dawson, Baltimore, MD (US); Seung Pil Yun, Baltimore, MD (US); and Magdalena Scully, Baltimore, MD (US)
Assigned to THE JOHNS HOPKINS UNIVERSITY, Baltimore, MD (US)
Filed by The Johns Hopkins University, Baltimore, MD (US)
Filed on Sep. 20, 2021, as Appl. No. 17/479,428.
Application 17/479,428 is a continuation of application No. 16/065,445, granted, now 11,123,405, previously published as PCT/US2016/068378, filed on Dec. 22, 2016.
Claims priority of provisional application 62/387,319, filed on Dec. 23, 2015.
Prior Publication US 2022/0111010 A1, Apr. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/26 (2006.01); A61K 9/00 (2006.01); A61K 38/38 (2006.01); A61K 47/60 (2017.01); A61K 47/68 (2017.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01)
CPC A61K 38/26 (2013.01) [A61K 9/0019 (2013.01); A61K 38/38 (2013.01); A61K 47/60 (2017.08); A61K 47/68 (2017.08); A61P 25/16 (2018.01); A61P 25/28 (2018.01)] 32 Claims
 
1. A method of treating a subject in need thereof, the method comprising
administering to a subject with a disease selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia type 1, and multiple sclerosis a pharmaceutically effective amount of a composition comprising a GLP-1r agonist PEGylated with polyethylene glycol (PEG) or derivatives thereof, which penetrates the blood brain barrier.